Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Treating cyclin E1 overexpressing/CCNE1-amplified cancers with INCB123667

Matteo Simonelli • 16 Sep 2024
ESMO 2024
General INCB123667

Matteo Simonelli, MD, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, Italy, comments on the promising results of INCB123667 in cyclin E1 overexpressing and CCNE1 amplified solid tumors, especially in ovarian cancer. There is strong rationale for continued development of INCB123667, especially given its preliminary efficacy as a monotherapy in a Phase I trial (NCT05238922). Future plans include combination therapies with other anticancer agents, emphasizing the potential of this drug in specific cancer settings. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Matteo Simonelli

KANDLELIT-001: MK-1084 monotherapy in KRAS G12C-mutated solid tumors
2:10
KANDLELIT-001: MK-1084 monotherapy in KRAS G12C-mutated solid tumors
Matteo Simonelli • 20 Oct 2025
Advancements in developing inhibitors for non-G12C KRAS mutations
0:38
Advancements in developing inhibitors for non-G12C KRAS mutations
Matteo Simonelli • 20 Oct 2025
KANDLELIT-001: MK-1084 monotherapy in KRAS G12C- mutated advanced solid tumors
2:10
KANDLELIT-001: MK-1084 monotherapy in KRAS G12C- mutated advanced solid tumors
Matteo Simonelli • 20 Oct 2025
Early results from INCB123667 in cyclin E1 overexpressing/CCNE1-amplified cancers
3:56
Early results from INCB123667 in cyclin E1 overexpressing/CCNE1-amplified cancers
Matteo Simonelli • 16 Sep 2024

Related Videos

Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The gut microbiome as a prognostic marker of side effects following radiotherapy
0:45
The gut microbiome as a prognostic marker of side effects following radiotherapy
Miguel Reis Ferreira • 16 May 2026
The content of VJOncology is intended for healthcare professionals